2. PI3K/Akt/mTOR
  3. Akt PI3K
  4. Recilisib

Recilisib  (Synonyms: ON 01210)

製品番号: HY-101625 純度: 99.94%
COA 取扱説明書 Technical Support

Recilisib (ON 01210) is a radioprotectant, which can activate AKT, PI3K activities in cells.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 334969-03-8

容量 価格（税別） 在庫状況 数量
>無料サンプル (0.1 - 0.2 mg)   今すぐ申し込む  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 121 在庫あり
Solution
10 mM * 1 mL in DMSO USD 121 在庫あり
Solid
5 mg $110 在庫あり
10 mg $150 在庫あり
25 mg $250 在庫あり
50 mg $400 在庫あり
100 mg $640 在庫あり
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 42 publication(s) in Google Scholar

Other Forms of Recilisib:

Recilisib 関連抗体

Top Publications Citing Use of Products

顧客検証

Cell Proliferation/Viability Assay
WB

    Recilisib purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Feb 12:139:156464.  [Abstract]

    Recilisib significantly reversed BRU-induced suppression of lipid metabolism in 143B, U2OS cells.

    Recilisib purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Sep 7:135:156022.  [Abstract]

    Recilisib partially reversed the proliferation inhibitory effect of HA in RBE and HuccT1 cells.

    Recilisib purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Sep 7:135:156022.  [Abstract]

    Recilisib indeed elevated the protein expression of P-mTOR (Ser2448), P-PI3K (Tyr607), and P-AKT (S473) following HA-induced inhibition PI3K-AKT-mTOR activator recilisib reversed the effect of HA on ICC.

    Recilisib purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2023 May;13(5):463-482.

    Recilisib (10 μM) activated the PI3K/AKT pathway (via recilisib), leading to an increased HCC cell viability in the cotreatment group compared to the Rk3 only group.

    Recilisib purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2023 May;13(5):463-482.

    Recilisib (10 μM) increased the protein expression of CDK4, cyclin D1 and P62, as well as decreased the protein expression of Bax, c-PARP and LC3II/LC3I in HepG2 and HCC-LM3 cells with 100 μM Rk3.

    Recilisib purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2020 Mar 15;147:79-88.  [Abstract]

    Measurement of ERK1/2 and NF-κB p65. Effect of GFP-A and Recilisib (activator of Akt) (10 μmol/L) on the expression of phosphorylated ERK1/2 in HT-29 cells. Cells are treated with 180 μg/mL GFP-A in the presence or absence of Recilisib for different durations of time.

    Recilisib purchased from MedChemExpress. Usage Cited in: Environ Toxicol. 2020 Dec;35(12):1299-1307.  [Abstract]

    FaDu cells with AGK overexpression is treated with the PI3K inhibitor LY294002, and Cal27 cells with AGK knockdown is treated with PI3K activator Recilisib (50 μM). The inhibitory effect of LY294002 and promoting effects of Recilisib on PI3K/Akt signaling is confirmed by Western blot analysis.

    Akt アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    Akt Akt1 Akt2 Akt3

    PI3K アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

    • 生物活性

    • プロトコル

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Recilisib (ON 01210) is a radioprotectant, which can activate AKT, PI3K activities in cells[1].

    IC50 & Target[1]

    PI3K

     

    体外実験

    Recilisib (up to 50 μM) shows a normal distribution of cells throughout the cell cycle, with a slight reduction in the number of cells in S-phase at 50 μM. Continuous exposure of Recilisib (100 μM) does not result in cell death. Recilisib treatment does not inhibit the colony forming potential of human bone marrow cells. Recilisib provides dose dependent protection of human bone marrow cells at all three doses of IR. Recilisib activates the phosphorylation of AKT and GSK3α/β in HFL cells. Recilisib increases PI3K activity in HFL-1 cells and murine bone marrow cells in response to radiation exposure. Recilisib treatment in combination with radiation alters the MAPK signaling pathway[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Recilisib 関連抗体
    体内実験

    Recilisib (500 mg/kg) significantly increases the rate of recovery and differentiation of primitive bone marrow myeloid progenitor cells in mice. Recilisib in combination with radiation reduces CFU numbers in mice, but the Recilisib-treated mice consistently retain a capability to form differentiated colonies. Recilisib treated mice have a progenitor cell population that is never completely depleted by radiation exposure[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    336.79

    分子式

    C16H13ClO4S
    CAS 番号
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(O)C1=CC=C(/C=C/S(=O)(CC2=CC=C(Cl)C=C2)=O)C=C1
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    溶剤 & 溶解度
    体外: 

    DMSO : 20 mg/mL (59.38 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.9692 mL 14.8460 mL 29.6921 mL
    5 mM 0.5938 mL 2.9692 mL 5.9384 mL
    10 mM 0.2969 mL 1.4846 mL 2.9692 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2 mg/mL (5.94 mM); Clear solution

      This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション

    純度: 99.94%

    COA (245 KB) LCMS (94 KB)

    取扱説明書 (2659 KB)
    参考文献
    キナーゼ実験
    [1]

    PI3-kinase assays are performed using exponentially growing HFL-1 or freshly harvested murine bone marrow cells that are treated with increasing concentrations of Recilisib Sodium for 2 hours and then irradiated with 10 Gy IR. These cells are then returned to the incubator for 2 to 24 hours and lysed in HEPES pH 7.5 lysis buffer. PI-3K is immunoprecipitated using an anti-PI3 Kinas polyclonal antibody for 2 hours at 4°C. Protein A/G PLUS-Agarose is incubated with immunoprecipitates for 8-16 hours at 4°C and the resulting immunoprecipitates washed with twice HEPES pH 7.5 lysis buffer and once with the kinase buffer (20 mM Tris pH 7.5, 1mM EGTA, 10mM MgCl2, 2 mM DTT, 0.01% NP-40). L-α-Phosphatidylinositol (12.5 mM) and ATP (10 µM) are added to the kinase buffer (60 µL per sample) and incubated at 30°C for 30 minutes. The reaction is stopped by addition of 100 µL of 1N HCl and extracted by addition of 200 µL CHCl3/CH3OH (1:1). The extracted samples are vortexed, centrifuged and the lower organic phases containing phospholipids are dried at 27°C for 2 hours. The dried samples are resuspended in 10 µL of PI-4-P standard (0.5 mL CHCl3, 0.5 mL CH3OH, 2.5 µL HCl) and spotted on TLC plates (VWR). The spotted plate is subjected to thin layer chromatography in CHCl3/CH3OH/NH4OH (40:40:15). The TLC plate is dried and subjected to autoradiography.

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。
    細胞実験
    [1]

    For cytotoxicity assays, cells (1.0×105 cells/mL HPGM) are treated with various concentrations of Recilisib Sodium or vehicle without radiation treatment for 2 or 24 hours. The cells are washed and plated into methocult using gridded dishes. The total number of colony forming units (CFUs) is determined 14 days post-plating by microscopic observation using an Olympus IMT-2 microscope.

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.9692 mL 14.8460 mL 29.6921 mL 74.2302 mL
    5 mM 0.5938 mL 2.9692 mL 5.9384 mL 14.8460 mL
    10 mM 0.2969 mL 1.4846 mL 2.9692 mL 7.4230 mL
    15 mM 0.1979 mL 0.9897 mL 1.9795 mL 4.9487 mL
    20 mM 0.1485 mL 0.7423 mL 1.4846 mL 3.7115 mL
    25 mM 0.1188 mL 0.5938 mL 1.1877 mL 2.9692 mL
    30 mM 0.0990 mL 0.4949 mL 0.9897 mL 2.4743 mL
    40 mM 0.0742 mL 0.3712 mL 0.7423 mL 1.8558 mL
    50 mM 0.0594 mL 0.2969 mL 0.5938 mL 1.4846 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Recilisib Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Recilisib334969-03-8ON 01210ON01210ON-01210AktPI3KPKBProtein kinase BPhosphoinositide 3-kinaseInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Recilisib
    製品番号:
    HY-101625
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.